Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2025-03-01
DOI
https://doi.org/10.1136/jitc-2024-010635
Citations
8
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
12.15

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer

Yoon‐Koo Kang, Hyung‐Don Kim, Min‐Hee Ryu, Hyungwoo Cho et al.
8 citations
Journal for ImmunoTherapy of Cancer
Gastric Cancer Management and Outcomes
12.15
article

Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer

Yoon‐Koo Kang, Hyung‐Don Kim, Min‐Hee Ryu, Hyungwoo Cho, Jong Seok Lee, Young Soo Park
article en
8 citations

Abstract

No abstract available for this paper.
Journal for ImmunoTherapy of CancerVol. 13(3)
Ulsan College (KR), Asan Medical Center (KR), University of Ulsan (KR)
Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 1%
Gastric Cancer Management and Outcomes
12.15
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.